Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.66 USD | +1.59% | +4.02% | -1.37% |
Financials (USD)
Sales 2024 * | 462M | Sales 2025 * | 543M | Capitalization | 1.94B |
---|---|---|---|---|---|
Net income 2024 * | 117M | Net income 2025 * | 161M | EV / Sales 2024 * | 3.18 x |
Net cash position 2024 * | 469M | Net cash position 2025 * | 700M | EV / Sales 2025 * | 2.28 x |
P/E ratio 2024 * |
17.4
x | P/E ratio 2025 * |
12.7
x | Employees | 167 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.79% |
Latest transcript on Catalyst Pharmaceuticals, Inc.
1 day | -1.56% | ||
1 week | +4.79% | ||
Current month | +8.97% | ||
1 month | +5.53% | ||
3 months | +17.14% | ||
6 months | +22.57% | ||
Current year | -2.44% |
Managers | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 76 | 01-12-31 |
Richard Daly
CEO | Chief Executive Officer | 62 | 15-02-18 |
Michael Kalb
DFI | Director of Finance/CFO | 53 | Dec. 31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 76 | 01-12-31 |
Donald Denkhaus
BRD | Director/Board Member | 78 | 15-02-18 |
David Tierney
BRD | Director/Board Member | 60 | 02-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.05% | 28 M€ | -0.39% | ||
0.32% | 25 M€ | -1.18% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 16.58 | +1.10% | 290 351 |
24-05-16 | 16.4 | -1.56% | 1,331,641 |
24-05-15 | 16.66 | +1.03% | 1,161,513 |
24-05-14 | 16.49 | +1.66% | 1,006,785 |
24-05-13 | 16.22 | +1.76% | 1,465,974 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.44% | 1.94B | |
-2.32% | 92.59B | |
+3.16% | 41.43B | |
-11.10% | 33.49B | |
+53.49% | 25.06B | |
-9.41% | 12.77B | |
-12.25% | 11.58B | |
-44.00% | 11.35B | |
+5.77% | 8.97B | |
-6.08% | 8.3B |
- Stock Market
- Equities
- CPRX Stock